[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622734":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":153,"collaborators":20,"id":155,"slug":156,"hasResults":157,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":20,"eligibilityCriteria":161,"healthyVolunteers":157,"sex":162,"minAge":163,"maxAge":20,"enrollmentInfo":164,"targetDuration":20,"studyType":167,"phases":168,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":186},{"fullName":5,"class":6},"AbbVie","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Venetoclax Monotherapy","EXPERIMENTAL","Participants will receive venetoclax at doses ramping up to the target dose, as part of the approximately 28 month study duration.",[13],"Drug: Venetoclax",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Venetoclax","Oral",[9],null,[22],{"name":23,"affiliation":5,"role":24},"ABBVIE INC.","STUDY_DIRECTOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"ABBVIE CALL CENTER","CONTACT","844-663-3742","abbvieclinicaltrials@abbvie.com",[32,46,52,57,66,76,85,90,99,104,109,113,117,121,130,135,144],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":20},"Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital \u002FID# 279178","RECRUITING","Nagoya","Aichi-ken","466-8650","Japan","JP",{"type":41,"coordinates":42},"Point",[43,44],136.90641,35.18147,{"lat":44,"lon":43},{"facility":47,"status":34,"city":35,"state":36,"zip":48,"country":38,"countryCode":39,"cosmosGeoPoint":49,"geoPoint":51,"contacts":20},"Nagoya City University Hospital \u002FID# 277580","467-8602",{"type":41,"coordinates":50},[43,44],{"lat":44,"lon":43},{"facility":53,"status":34,"city":54,"state":55,"zip":56,"country":38,"countryCode":39,"cosmosGeoPoint":20,"geoPoint":20,"contacts":20},"University of Fukui Hospital \u002FID# 279173","Yoshida-gun","Fukui","910-1104",{"facility":58,"status":34,"city":59,"state":59,"zip":60,"country":38,"countryCode":39,"cosmosGeoPoint":61,"geoPoint":65,"contacts":20},"Kyushu University Hospital \u002FID# 277582","Fukuoka","812-8582",{"type":41,"coordinates":62},[63,64],130.41667,33.6,{"lat":64,"lon":63},{"facility":67,"status":34,"city":68,"state":69,"zip":70,"country":38,"countryCode":39,"cosmosGeoPoint":71,"geoPoint":75,"contacts":20},"Gunma University Hospital \u002FID# 277576","Maebashi","Gunma","371-8511",{"type":41,"coordinates":72},[73,74],139.08333,36.4,{"lat":74,"lon":73},{"facility":77,"status":34,"city":78,"state":78,"zip":79,"country":38,"countryCode":39,"cosmosGeoPoint":80,"geoPoint":84,"contacts":20},"Hiroshima University Hospital \u002FID# 279172","Hiroshima","734-8551",{"type":41,"coordinates":81},[82,83],132.45,34.4,{"lat":83,"lon":82},{"facility":86,"status":34,"city":87,"state":88,"zip":89,"country":38,"countryCode":39,"cosmosGeoPoint":20,"geoPoint":20,"contacts":20},"NHO Mito Medical Center \u002FID# 279175","Higashiibaraki-gun","Ibaraki","311-3193",{"facility":91,"status":34,"city":92,"state":92,"zip":93,"country":38,"countryCode":39,"cosmosGeoPoint":94,"geoPoint":98,"contacts":20},"University Hospital Kyoto Prefectural University of Medicine \u002FID# 277584","Kyoto","602-8566",{"type":41,"coordinates":95},[96,97],135.75385,35.02107,{"lat":97,"lon":96},{"facility":100,"status":34,"city":101,"state":102,"zip":103,"country":38,"countryCode":39,"cosmosGeoPoint":20,"geoPoint":20,"contacts":20},"Kindai University Hospital \u002FID# 277587","Sakai-shi","Osaka","590-0197",{"facility":105,"status":34,"city":106,"state":107,"zip":108,"country":38,"countryCode":39,"cosmosGeoPoint":20,"geoPoint":20,"contacts":20},"The University of Tokyo Hospital \u002FID# 279174","Bunkyo-ku","Tokyo","113-8654",{"facility":110,"status":34,"city":111,"state":107,"zip":112,"country":38,"countryCode":39,"cosmosGeoPoint":20,"geoPoint":20,"contacts":20},"National Cancer Center Hospital \u002FID# 279076","Chuo-Ku","104-0045",{"facility":114,"status":34,"city":115,"state":107,"zip":116,"country":38,"countryCode":39,"cosmosGeoPoint":20,"geoPoint":20,"contacts":20},"The Cancer Institute Hospital Of JFCR \u002FID# 277579","Koto-ku","135-8550",{"facility":118,"status":34,"city":119,"state":107,"zip":120,"country":38,"countryCode":39,"cosmosGeoPoint":20,"geoPoint":20,"contacts":20},"Japanese Red Cross Medical Center \u002FID# 277577","Shibuya-ku","150-8935",{"facility":122,"status":34,"city":123,"state":107,"zip":124,"country":38,"countryCode":39,"cosmosGeoPoint":125,"geoPoint":129,"contacts":20},"National Hospital Organization Disaster Medical Center \u002FID# 277741","Tachikawa","190-0014",{"type":41,"coordinates":126},[127,128],139.41891,35.7091,{"lat":128,"lon":127},{"facility":131,"status":34,"city":132,"state":133,"zip":134,"country":38,"countryCode":39,"cosmosGeoPoint":20,"geoPoint":20,"contacts":20},"University of Yamanashi Hospital \u002FID# 279179","Chuo-shi","Yamanashi","409-3898",{"facility":136,"status":34,"city":137,"state":20,"zip":138,"country":38,"countryCode":39,"cosmosGeoPoint":139,"geoPoint":143,"contacts":20},"Chiba Cancer Center \u002FID# 279177","Chiba","260-0801",{"type":41,"coordinates":140},[141,142],140.11667,35.6,{"lat":142,"lon":141},{"facility":145,"status":34,"city":146,"state":20,"zip":147,"country":38,"countryCode":39,"cosmosGeoPoint":148,"geoPoint":152,"contacts":20},"Nagano Red Cross Hospital \u002FID# 279774","Nagano","380-8582",{"type":41,"coordinates":149},[150,151],138.18333,36.65,{"lat":151,"lon":150},{"type":154,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100622734","phase-2-study-to-assess-change-in-disease-activity-of-oral-venetoclax-in-adult-participants-with-recurring-relapsed-or-refractory-rr-waldenstrm-macroglobulinemia-wmlymphoplasmacytic-lymphoma-lpl-100622734",false,"NCT07387471","Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R\u002FR) Waldenström Macroglobulinemia (WM)\u002FLymphoplasmacytic Lymphoma (LPL)","A Phase 2 Study of Venetoclax Monotherapy in Japanese Subjects With Relapsed or Refractory Waldenström Macroglobulinemia\u002FLymphoplasmacytic Lymphoma","Inclusion Criteria:\n\n* Documented diagnosis of Waldenström macroglobulinemia(WM) \u002Flymphoplasmacytic lymphoma (LPL) according to the 5th edition of the World Health Organization (WHO) classification and\u002For documented clinicopathological diagnosis of WM in accordance with the consensus panel of the second International Workshop on WM (IWWM).\n* At least one prior standard therapy for WM\u002FLPL.\n* Measurable disease, defined as follows:\n\n  * WM type LPL population: Immunoglobulin M (IgM) \\>= 500 mg\u002FdL per central laboratory (approximately 14 participants)\n  * Non-IgM type LPL population or IgM \\\u003C 500 mg\u002FdL: A measurable node having a longest diameter (LDi) greater than 1.5 cm, or a measurable extranodal disease having a LDi greater than 1.0 cm, according to contrast-enhanced computed tomography (CT) scan. (up to 2 participants)\n* Requires systemic anti-cancer treatment for WM\u002FLPL, according to the investigator.\n* Eastern Cooperative Oncology Group Performance Status \\\u003C = 2\n* Adequate organ and bone marrow function\n\nExclusion Criteria:\n\n* History of prior exposure to venetoclax or BCL-2 targeted therapy.\n* Uncontrolled active systemic infection.\n* Known bleeding disorders (e.g., von Willebrand's disease or hemophilia).","ALL","18 Years",{"count":165,"type":166},14,"ESTIMATED","INTERVENTIONAL",[169],"PHASE2","Lymphoplasmacytic Lymphoma (LPL) is a rare type of low-grade B-cell lymphoma. The purpose of this study is to assess the change in disease activity of adult participants with relapsed or refractory Waldenström macroglobulinemia(WM)\u002FLPL receiving venetoclax.\n\nVenetoclax is being investigated in the treatment of WM\u002FLPL. Participants will receive oral venetoclax at doses ramping up to the target dose, as part of treatment. Approximately 14 adult participants with WM\u002FLPL will be enrolled in the study at approximately 20 sites in Japan.\n\nParticipants will receive oral venetoclax at doses ramping up to the target dose. The total study duration is approximately 28 months.\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, and checking for side effects.",[172,173],"Waldenstrom Macroglobulinemia","Lymphoplasmacytic Lymphoma",[172,173,17,175,176],"Venclexta","Cancer","2026-05-27",{"date":179,"type":180},"2026-05-29","ACTUAL",{"date":182,"type":180},"2026-03-17",{"date":184,"type":166},"2028-07",{"name":5,"class":6},17]